Xponance’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Xponance’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,162	Closed	-$342K	–	1245
2022 Q1	$342K	Buy	4,162 +250	+6%	+$25.6K	0.01%	1005
2021 Q4	$574K	Buy	3,912 +150	+4%	+$23.3K	0.01%	852
2021 Q3	$666K	Sell	3,762 -67	-2%	-$10.8K	0.01%	752
2021 Q2	$618K	Buy	+3,829	New	+$615K	0.01%	814
2021 Q1	–	Sell	-1,214	Closed	-$267K	–	1063
2020 Q4	$267K	Buy	+1,214	New	+$262K	0.01%	981

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Xponance's MRTX Position: Q2 2022 in Review

Xponance sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 4,162 shares — an estimated $342K sold.

Xponance first reported a position in MRTX in Q4 2020 and held it in 5 quarters. The position peaked at $666K in Q3 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

Xponance reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Xponance sold 4,162 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $342K.
Xponance first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
Xponance's Mirati Therapeutics, Inc. Common Stock position peaked at $666K in Q3 2021.
230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Xponance's 13F filing for Q2 2022, filed 2 Aug 2022.